INS and type 2 diabetes mellitus: In a study performed by Rosenstock at al., empagliflozin caused an improvement of glycemic control and weight reduction in obese patients with T2DM with inadequate control on high multiple dose insulin without increasing the risk of hypoglycemia and with lower insulin requirements [93].